pomalidomide has been researched along with Angiogenesis, Pathologic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berenson, JR; Chen, H; Gillespie, A; Li, M; Sanchez, E; Tang, G; Wang, CS | 1 |
| Bartlett, JB; Chen, RS; Hariri, RJ; Hughes, CC; Lu, L; Man, HW; Muller, GW; Payvandi, F; Schafer, PH; Stirling, DI; Wu, L; Zhang, LH | 1 |
| Lacy, MQ; Rajkumar, SV | 1 |
| Crane, E; List, A | 1 |
| Bührer, C; Costa-Blechschmidt, C; Fichtner, I; Henze, G; Moderegger, E; Pfau, M; Seeger, K; Shalapour, S; Taube, T; van Landeghem, FK; Wellmann, S; Zelmer, A | 1 |
| Czuczman, MS; Deeb, G; Hernandez-Ilizaliturri, FJ; Knight, J; Reddy, N; Roth, M; Vaughn, M; Wallace, P | 1 |
3 review(s) available for pomalidomide and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Mice; Mice, SCID; Multiple Myeloma; Neovascularization, Pathologic; Oligopeptides; Thalidomide; Xenograft Model Antitumor Assays | 2017 |
Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.
Topics: Cytokines; Humans; Immunologic Factors; Multiple Myeloma; Neovascularization, Pathologic; Primary Myelofibrosis; Signal Transduction; Thalidomide | 2010 |
Immunomodulatory drugs.
Topics: Humans; Immunosuppressive Agents; Interleukin-12; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Multiple Myeloma; Myelodysplastic Syndromes; Neovascularization, Pathologic; T-Lymphocytes; Thalidomide | 2005 |
3 other study(ies) available for pomalidomide and Angiogenesis, Pathologic
| Article | Year |
|---|---|
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
Topics: Adherens Junctions; Angiogenesis Inhibitors; Animals; Antigens, CD; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; beta Catenin; Cadherins; Cell Differentiation; Cell Hypoxia; Cell Line, Tumor; Cells, Cultured; Endothelial Cells; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; In Vitro Techniques; Lenalidomide; Lung Neoplasms; Melanoma, Experimental; Mice; Microcirculation; Neoplasm Metastasis; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Pregnancy; Proto-Oncogene Proteins c-akt; Thalidomide; Umbilical Arteries | 2009 |
The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo.
Topics: Animals; Apoptosis; Blood Vessels; Caspase 3; Cell Proliferation; Child, Preschool; Female; Humans; Infant; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stromal Cells; Thalidomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Cytotoxicity, Immunologic; Dendritic Cells; Drug Interactions; Immunohistochemistry; Immunosuppressive Agents; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, SCID; Microcirculation; Neovascularization, Pathologic; Rituximab; Thalidomide | 2008 |